D
DAWN
Day One Biopharmaceuticals, Inc.
This stock has been delisted.
News
Press Releases
Financial Reports
Profile
TipRanks·04/23 13:21
Day One Biopharmaceuticals Completes Merger, Goes Private
PUBT·04/23 12:33
Servier completes acquisition of Day One for $21.50 per share
Reuters·04/23 12:30
SERVIER COMPLETES THE ACQUISITION OF DAY ONE BIOPHARMACEUTICALS
Seeking Alpha·04/20 15:55
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on
TipRanks·04/06 20:40
JonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)
Seeking Alpha·04/02 16:49
Biotech Is Holding Steady In 2026
Seeking Alpha·03/23 18:47
Top performing mid-cap stocks YTD as volatility hits markets
Simply Wall St·03/12 01:34
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story
Benzinga·03/11 14:34
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Dow Jones·03/11 14:26
Day One Biopharm Price Target Cut to $21.50/Share From $27.00 by JP Morgan
Dow Jones·03/11 14:26
Day One Biopharm Cut to Neutral From Overweight by JP Morgan
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.